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Background: Vascular closure devices (VCD) are frequently used in patients undergoing cardiac catheterization. Their safety and efficacy in 
patients following cardiac transplantation have not been studied.
Methods: Retrospective review of cardiac transplant recipients undergoing catheterization at our center, with a follow up of ≥4 months. Analysis is 
performed based on whether or not a VCD was used.
Results: Between January 2005 and June 2009, 233 cardiac transplant recipients underwent 413 cardiac catheterization procedures for their 
annual evaluation. A VCD was used in 206 of these procedures: angioseal in 143, starclose in 35, and perclose in 28. This was successful in 202 
procedures (98.1%); device failure occurred in 2 perclose and 2 starclose patients. Hemostasis was achieved by primary manual compression 
following 207 procedures. The use of a VCD was associated with a higher prevalence of male sex, hypertension and dyslipidemia, and a lower 
prevalence of history of peripheral arterial disease (Table). One patient (0.5%) in the manual compression group developed a pseudoaneurysm while 
in-hospital, another patient (0.5%) had recurrent Staphylococcus Aureus abscess in the groin after 3 months that required drainage and antibiotic 
therapy. No complications were noted in the VCD group (P=NS); particularly, there were no infections at the access site.
Conclusions: The use of vascular closure devices in cardiac transplant recipients post cardiac catheterization appears to be safe and effective. 
Baseline characteristics according to the use of a vascular closure device.
Manual Compression
(n = 207)
Closure Device
(n = 206)
P-Value
Age (years) 57.6 ± 14.7 58.5 ± 12.9 0.83
Male sex 148 (71.5) 169 (82.0) 0.01
Race (Caucasian) 181 (87.4) 185 (89.8) 0.45
Body surface area (m2) 1.94 ± 0.22 1.97 ± 0.22 0.34
Hypertension 136 (65.7) 164 (79.6) 0.002
Diabetes 42 (20.3) 51 (24.8) 0.28
Smoking history 91 (44.0) 107 (51.9) 0.09
Dyslipidemia 158 (76.3) 175 (85.0) 0.03
Renal insufficiency 31 (15.0) 38 (18.5) 0.34
Family history of CAD 30 (14.5) 44 (21.4) 0.07
Peripheral arterial disease 14 (6.8) 5 (2.4) 0.04
Blood Pressure (mmHg)
Systolic 129 ± 21 130 ± 24 0.70
Diastolic 79 ± 11 80 ± 12 0.24
Mean 102 ± 14 102 ± 16 0.33
Serum creatinine (mg/dl) 1.55 ± 0.91 1.60 ± 0.75 0.11
Hematocrit (%) 39.5 ± 4.6 39.2 ±4.4 0.45
Platelet count (x103/m3) 240.5 ± 92.1 240.0 ± 67.6 0.30
Partial Thromboplastin Time (sec) 29.6 ± 11.2 28.8 ± 8.1 0.36
International Normalized Ratio 1.0 ± 0.1 1.0 ± 0.2 0.88
Use of antiplatelets and anticoagulants
Clopidogrel 28 (15.5) 27 (14.2) 0.73
Heparin 13 (7.2) 17 (9.0) 0.53
Glycoprotein IIbIIIa inhibitor 1 (0.6) 2 (1.1) 0.39
Coumadin 3 (1.7) 7 (3.7) 0.23
CAD, coronary artery disease; continuous variables are reported as mean ± standard deviation; categorical variables are reported as number (%).
